Evidence map›Paper›PMID 35450373›Full record

ArticleACS medicinal chemistry letters2022

Azapodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols.

Arvin M Gouw, Vineet Kumar, Angel Resendez, Fidelia B Alvina, Natalie S Liu, Katherine Margulis, Ling Tong, Richard N Zare, Sanjay V Malhotra, Dean W Felsher

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Arvin M GouwDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, United States.
Vineet KumarDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, United States.
Angel ResendezDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, United States.
Fidelia B AlvinaDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, United States.ORCID https://orcid.org/0000-0001-7552-1001
Natalie S LiuDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, United States.
Katherine MargulisDepartment of Chemistry, School of Humanities and Sciences, Stanford University, Stanford, California 94305, United States.
Ling TongDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, United States.
Richard N ZareDepartment of Chemistry, School of Humanities and Sciences, Stanford University, Stanford, California 94305, United States.ORCID https://orcid.org/0000-0001-5266-4253
Sanjay V MalhotraDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, United States.
Dean W FelsherDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, United States.ORCID https://orcid.org/0000-0003-2496-523X
Stanford University · USOregon Health & Science University · US

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Targeting the MYC Pathway for the Treatment of CancerR35CA253180 · NCI · STANFORD UNIVERSITY · PI DEAN W FELSHER · 2020 to 2026
$6.9M
Modeling and Predicting Therapeutic Resistance of CancerU01CA188383 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, GAMBHIR, SANJIV S · 2014 to 2018
$3.2M
Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry ImagingR01CA184384 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, ZARE, RICHARD N · 2014 to 2018
$2.7M
(PQ7)Multi-scale Analysis of Tumor Microenvironment HeterogeneityR01CA208735 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W · 2017 to 2019
$2.2M
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)T32CA196585 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, RAO, JIANGHONG · 2015 to 2019
$1.8M
The Development of 4-methylumbelliferone Pro-drugs to Prevent Autoimmune DiabetesR01DK114174 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2018 to 2020
$1.3M
NCATS NIH HHS UL1 TR003142NCI NIH HHS R01 CA184384NCI NIH HHS R01 CA208735NCI NIH HHS R35 CA253180NCI NIH HHS T32 CA196585NCI NIH HHS U01 CA188383NIDDK NIH HHS R01 DK114174
6 · The paper itself

Abstract

A natural compound screen identified several anticancer compounds, among which azapodophyllotoxin (AZP) was found to be the most potent. AZP caused decreased viability of both mouse and human lymphoma and renal cell cancer (RCC) tumor-derived cell lines. Novel AZP derivatives were synthesized and screened identifying compound NSC750212 to inhibit the growth of both lymphoma and RCC both in vitro and in vivo. A nanoimmunoassay was used to assess the NSC750212 mode of action in vivo. On the basis of the structure of AZP and its mode of action, AZP disrupts tubulin polymerization. Through desorption electrospray ionization mass spectrometry imaging, NSC750212 was found to inhibit lipid metabolism. NSC750212 suppresses monoglycerol metabolism depleting lipids and thereby inhibits tumor growth. The dual mode of tubulin polymerization disruption and monoglycerol metabolism inhibition makes NSC750212 a potent small molecule against lymphoma and RCC.

Identifiers

PMID35450373
PMCPMC9014495
OpenAlexW4220689415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.